The Biotech Growth Trust PLC (BIOGL.XC)
- Previous Close
741.00 - Open
734.00 - Bid --
- Ask --
- Day's Range
734.00 - 734.00 - 52 Week Range
734.00 - 1,064.00 - Volume
229 - Avg. Volume
0 - Market Cap (intraday)
198.41M - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
273.88 - EPS (TTM)
2.68 - Earnings Date Jun 3, 2025 - Jun 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
The Biotech Growth Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the biotechnology sector. The fund invests in stocks of companies across all market capitalizations. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index. It was previously known as Finsbury Emerging Biotechnology Trust PLC. The Biotech Growth Trust PLC was formed on May 20, 1997 and is domiciled in the United Kingdom.
www.biotechgt.com/index.php/biog/home/overview/--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: BIOGL.XC
View MorePerformance Overview: BIOGL.XC
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOGL.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOGL.XC
View MoreValuation Measures
Market Cap
198.65M
Enterprise Value
--
Trailing P/E
3.33
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.02
Price/Book (mrq)
0.72
Enterprise Value/Revenue
2.81
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
95.33%
Return on Assets (ttm)
16.98%
Return on Equity (ttm)
29.79%
Revenue (ttm)
101.17M
Net Income Avi to Common (ttm)
96.45M
Diluted EPS (ttm)
2.68
Balance Sheet and Cash Flow
Total Cash (mrq)
3.97M
Total Debt/Equity (mrq)
11.02%
Levered Free Cash Flow (ttm)
44.24M